TrialAmerican journal of respiratory and critical care medicine2022

Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.

Gerard J Criner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.